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Long-term peritoneal dialysis induces peritoneal fibrosis with
submesothelial fibrotic tissue. Although angiogenesis and
inflammatory mediators are involved in peritoneal fibrosis,
precise molecular mechanisms are undefined. To study this,
we used microarray analysis and compared gene expression
profiles of the peritoneum in control and chlorhexidine
gluconate (CG)-induced peritoneal fibrosis mice. One of the
43 highly upregulated genes was pleiotrophin, a midkine
family member, the expression of which was also
upregulated by the solution used to treat mice by peritoneal
dialysis. This growth factor was found in fibroblasts and
mesothelial cells within the underlying submesothelial
compact zones of mice, and in human peritoneal biopsy
samples and peritoneal dialysate effluent. Recombinant
pleiotrophin stimulated mitogenesis and migration of mouse
mesothelial cells in culture. We found that in wild-type mice,
CG treatment increased peritoneal permeability (measured
by equilibration), increased mRNA expression of TGF-b1,
connective tissue growth factor and fibronectin, TNF-a and
IL-1b expression, and resulted in infiltration of CD3-positive T
cells, and caused a high number of Ki-67-positive
proliferating cells. All of these parameters were decreased in
peritoneal tissues of CG-treated pleiotrophin-knockout mice.
Thus, an upregulation of pleiotrophin appears to play a role
in fibrosis and inflammation during peritoneal injury.
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Continuous ambulatory peritoneal dialysis (PD) is a
preferred method of home dialysis for patients with end-
stage renal failure.1 Long-term use of PD induces peritoneal
fibrosis characterized with the presence of submesothelial
fibrotic tissue and increased peritoneal vascularization with
vasculopathy.2 Peritoneal fibrosis occurs in long-term con-
tinuous ambulatory PD patients in response to a variety of
injuries, including bioincompatible dialysate solutions, peri-
tonitis, uremia, and chronic inflammation.2,3 Previous
reports show that several profibrotic and proinflammatory
mediators are upregulated upon induction of peritoneal
fibrosis, such as transforming growth factor-b (TGF-b) and
interleukin-6 (IL-6).4–6 Although proinflammatory, angio-
genic, and profibrotic cytokines such as IL-1b, vascular
endothelial growth factor, and TGF-b are presumed to be
involved in the pathogenesis, precise molecular mechanisms
that lead to peritoneal sclerosis and encapsulating peritoneal
sclerosis are still elusive.7–9 To identify the novel genes
possibly involved in the development of peritoneal fibrosis,
we compared gene expression profiles of the peritoneum in
chlorhexidine gluconate (CG)-induced peritoneal fibrosis
and control mice using microarray.
Microarray analysis is a powerful tool to identify novel
genes and pathways involved in the development of
peritoneal fibrosis. Although a few papers report microarray
analysis for endothelial cells in rat peritoneal dialysate
infusion model,10 analysis for whole mouse gene sets over
39,000 transcripts has not been investigated yet. In this study,
we performed microarray analysis using a mouse model of
peritoneal fibrosis and selected the genes that changed greatly
in peritoneal fibrosis and those that were also present in
mesothelial cells. This approach can allow us to specify the
genes associated with peritoneal injury.
Here we show that one of the highly upregulated secreted
proteins during the development of peritoneal fibrosis is
pleiotrophin (PTN). PTN is an 18-kDa secreted protein,
belonging to the midkine family and has functions similar to
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midkine.11 The receptors for PTN are the receptor protein
tyrosine phosphatase b/z (RPTPb/z), anaplastic lymphoma
tyrosine kinase (ALK), and syndecan-3.12 PTN has been
shown to promote cell growth, migration, oncogenesis, and
angiogenesis.11 However, the role of PTN in peritoneal
fibrosis remains unknown. To elucidate the role of PTN in
peritoneal injury, we examined the PTN expression in a
mouse model of peritoneal fibrosis and in human peritoneal
biopsy samples. We also investigated the functional signifi-
cance of PTN by using PTN-deficient mice.13
RESULTS
To screen novel genes involved in development of peritoneal
fibrosis, we compared the gene expression profiles between
phosphate buffered saline (PBS)-injected and CG-injected
mice three times a week for 3 weeks. As a control, PBS-
injected wild-type mice showed no peritoneal fibrosis.
CG-injected mice showed marked thickened submesothelial
peritoneal membrane compared with PBS-injected mice
(Figure 1a, CG-injected mice: 228 mm vs. PBS-injected mice:
34 mm). We performed microarray analysis using parietal
peritoneum in mice at 21 days after PBS and CG treatment.
We identified genes differentially expressed between PBS- and
CG-injected mice, which were also expressed in murine
cultured mesothelial cells. Table 1 shows one downregulated
and 43 upregulated genes that were expressed by eightfold or
greater in CG-treated mice than that in PBS-treated wild-type
mice, and which were expressed in the cultured mesothelial
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Figure 1 |PTN expression in a mouse model of peritoneal fibrosis. (a) Microscopic examination of peritoneal fibrosis model mice. C57BL/
6J wild-type mice (WT) treated with phosphate-buffered saline (PBS) showed no fibrosis in the peritoneum. Chlorhexidine gluconate
(CG)-treated mice exhibited marked peritoneal fibrosis with moderate infiltration of mononuclear cells on day 21 (n¼ 3, each, original
magnification  20). Pleiotrophin (PTN) mRNA expression (b) or protein (c) in the peritoneum of PBS- or CG-treated mice was analyzed by
real-time reverse transcriptase-polymerase chain reaction analysis or western blot analysis, respectively. GAPDH was used as internal control
(n¼ 5, each). (d) Immunohistochemical study for PTN (brown). Mesothelial cells and the cells in submesothelial layer were positive for PTN.
(e) Double immunohistochemical study for PTN (brown) and S100A4 (blue). Some of PTN-positive cells were also positive for S100A4
(arrow). (f) Mice receiving daily intraperitoneal injection of 7% peritoneal dialysis fluid (PDF) for 4 weeks showed increased submesothelial
layer thickness by Masson’s trichrome staining (MT) and upregulated PTN protein in the submesothelial layer (n¼ 5, each). (g) Western blot
analysis showed that PTN protein in PDF-treated mice was 1.9 times higher than the control. GAPDH was used as internal control.
Mean±s.e. *Po0.05, **Po0.01 vs. PBS. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; wk, week.
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cells. Expression of extracellular matrix-related genes, includ-
ing procollagen type VIII a1, was increased in peritoneal
fibrosis model. Inflammatory cytokines including IL-6 were
also upregulated. Among these upregulated genes, we focused
on secreted proteins. One of them was PTN, which is an
18-kDa secreted protein and has been reported to promote
mitogenesis and chemotaxis in cultured cells. Microarray
analysis showed that PTN signal in the peritoneal membrane
in the CG-injected wild-type mice was upregulated by 11-fold
compared with PBS-injected mice (Table 1). Next, we
confirmed the increase of PTN mRNA expression in the
peritoneum of CG-treated mice by real-time reverse tran-
scriptase-polymerase chain reaction (RT-PCR) analysis
(Figure 1b). PTN mRNA in the peritoneum of CG-treated
mice was gradually increased and peaked at 3 weeks by 39-
fold compared with that in PBS-treated mice at 28 days, and
was high until 4 weeks (Figure 1b). Diluted CG, such as 0.03
or 0.01%, induced weaker expression of PTN mRNA than
0.1% CG (Figure 1b). Western blot analysis also showed that
PTN protein in the peritoneum of CG-treated mice was
gradually upregulated and was highest at 3 weeks by 3.9-fold,
as compared with that of PBS-treated mice (Figure 1c). A low
concentration of 1:10 diluted CG induced less PTN
expression (Figure 1c). Immunohistochemical study showed
Table 1 | Genes changed in parietal peritoneum in chlorhexidine gluconate (CG)-treated mice compared with phosphate-
buffered saline-treated mice after 3 weeks of CG treatment and in the presence of cultured mesothelial cells
Gene title ID
Fold change of gene up-
or downregulated in CG-treated
mice compared with PBS-treated mice
Gene
symbol
Glucocortoid-regulated inflammatory prostaglandin GH synthase (griPGHS) M94967 168.897 Ptgs2
Procollagen, type VIII, alpha 1 NM_007739 73.51669 Col8a1
DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked AA210261 55.71524 Ddx3y
Eukaryotic translation initiation factor 2, subunit 3, structural gene Y-linked NM_012011 48.50293 Eif2s3y
A disintegrin and metallopeptidase domain 12 (meltrin alpha) NM_007400 42.22425 Adam12
Interleukin 6 NM_031168 25.99208 Il6
Chemokine (C-X-C motif) ligand 1 NM_008176 24.25147 Cxcl1
Matrix metallopeptidase 14 (membrane-inserted) NM_008608 24.25147 Mmp14
Chemokine (C-C motif) ligand 7 AF128193 17.14838 Ccl7
Ankyrin repeat domain 1 (cardiac muscle) AK009959 16 Ankrd1
Leucine-rich repeat containing 15 AK017350 14.92853 Lrrc15
Chemokine (C-C motif) ligand 2 AF065933 14.92853 Ccl2
Interferon, alpha-inducible protein AK019325 14.92853 G1p2
Runt-related transcription factor 1 NM_009821 12.12573 Runx1
Interferon regulatory factor 7 NM_016850 12.12573 Irf7
Collagen triple helix repeat containing 1 AK003674 12.12573 Cthrc1
Cytochrome P450, family 7, subfamily b, polypeptide 1 NM_007825 11.31371 Cyp7b1
Pleiotrophin BC002064 11.31371 Ptn
Procollagen, type V, alpha 2 AV229424 11.31371 Col5a2
Fibronectin 1 BM234360 10.55606 Fn1
Chondroitin sulfate proteoglycan 2 NM_019389 10.55606 Cspg2
Thrombospondin 1 AI385532 10.55606 Thbs1
Membrane-spanning 4-domains, subfamily A, member 4C NM_022429 10.55606 Ms4a4c
Lysyl oxidase M65143 10.55606 Lox
Growth differentiation factor 15 NM_011819 9.849155 Gdf15
Dynamin 3, opposite strand BB542096 9.849155 Dnm3os
RNA imprinted and accumulated in nucleus BB649603 9.849155 Rian
WNT1-inducible signaling pathway protein 1 NM_018865 9.849155 Wisp1
Secreted frizzled-related sequence protein 1 BI658627 9.849155 Sfrp1
Procollagen, type III, alpha 1 AW550625 9.849155 Col3a1
Signal transducer and activator of transcription 2 AF088862 9.189587 Stat2
20-50 Oligoadenylate synthetase-like 2 BQ033138 9.189587 Oasl2
Tenascin C NM_011607 9.189587 Tnc
Neural cell adhesion molecule 1 BB698413 8.574188 Ncam1
Integrin a5 (fibronectin receptor alpha) BB493533 8.574188 Itga5
Tribbles homolog 3 (Drosophila) BB508622 8.574188 Trib3
Gap junction membrane channel protein alpha 1 M63801 8.574188 Gja1
Interferon-induced protein with tetratricopeptide repeats 2 NM_008332 8.574188 Ifit2
Serine (or cysteine) peptidase inhibitor, clade A, member 3N NM_009252 8.574188 Serpina3n
Lysyl oxidase-like 2 AF117951 8 Loxl2
GLI pathogenesis-related 2 BM208214 8 Glipr2
20-50 Oligoadenylate synthetase-like 1 AB067533 8 Oasl1
Tissue inhibitor of metalloproteinase 1 BC008107 8 Timp1
Immunoglobulin heavy chain 4 (serum IgG1) BC008237 0.033493 Igh4
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that PTN was positive in the spindle-shaped cells and partly
in mesothelial cells within the submesothelial layer (Figure
1d). Some of the spindle-shaped cells were also positive for a
marker for fibroblasts S100A4, indicating that spindle-shaped
cells were fibroblasts (Figure 1e). Next, we examined the
effects of infusing peritoneal dialysis fluid (PDF) via a
peritoneal catheter on expression of PTN. Mice receiving
daily intraperitoneal injection of 7% PDF for 4 weeks showed
increased PTN protein in the submesothelial layer with mild
peritoneal fibrosis (Figure 1f). PTN protein in PDF-treated
mice was 1.9 times higher than control mice, as observed by
western blot analysis (Figure 1g).
We examined PTN expression in human biopsy samples at
the insertion or removal of peritoneal catheters. PTN was
expressed in human peritoneal biopsy samples by RT-PCR
method (Figure 2a). Immunohistochemical study showed
that PTN was located both in the mesothelial cells (arrows)
and in the interstitial cells of peritoneal biopsy samples at the
withdrawal from 5-year PD treatment (patient A), which was
consistent with a mouse model of peritoneal fibrosis (Figure
2b). We examined whether peritoneal dialysate effluent
contained PTN. Western blot analysis showed that peritoneal
dialysates from six patients contained 15- and 18-kDa PTN
(Figure 2c). The main form of PTN in peritoneal dialysate
was 15 kDa. Patient B was a 54-year-old woman suffering
from nephrosclerosis with a 2-year PD duration, patient C
was a 47-year-old man suffering from diabetic nephropathy
with a 2-year PD duration, and patient D was a 29-year-old
woman suffering from immunoglobulin A nephropathy with
a 1-year PD duration. Next, we examined PD effluent from
patients with peritonitis. Patients E and F were 80- and 86-
year-old women suffering from peritonitis by Staphylococcus
aureus, respectively. PD effluents from patients with perito-
nitis tended to be high PTN levels. These results indicate that
PTN exists in human peritoneal membrane and is detectable
in peritoneal dialysate effluent.
Next, we investigated functional roles of PTN in cultured
mouse peritoneal mesothelial cells. PTN exerts its effect, such
as proliferation and chemotaxis, by binding its receptors,
RPTPb/z, ALK, and syndecan-3. We examined expression of
Ptprz1, which encodes RPTPb/z, ALK, and syndecan-3 in
cultured mesothelial cells. Ptprz1 mRNA expression was
detected in mesothelial cells but not in fibroblasts, macro-
phage cell line RAW264.7, mouse T-lymphoma cell line
BW5147, mouse B-cell leukemia cell line BCL1-B20, or
endothelial cell line bEnd.3 by real-time RT-PCR analyses
(Figure 3a). Syndecan-3 mRNA expression was high in
mesothelial cells and was also positive in fibroblasts,
macrophages, and endothelial cells (Figure 3b). ALK mRNA
expression was not detectable. PTN (1 ng/ml) stimulated
proliferation in cultured mesothelial cells by 1.7-fold
compared with vehicle-treated cells (Figure 3c). Angiotensin
II and platelet-derived growth factor-BB stimulation showed
less potent activity in cell proliferation than PTN, and
endothelial growth factor treatment (100 ng/ml) revealed a
similar potency to PTN stimulation (Figure 3c). PTN also
induced mesothelial cell migration in the analysis of modified
Boyden chamber method by threefold, as compared with
vehicle-treated cells (Figure 3d). In vitro, fibroblasts cell line
NIH3T3 fibroblasts showed higher PTN expression than
mesothelial cells. RAW 264.7, mouse BW5147, BCL1-B20,
and bEnd.3 showed virtually no expression of PTN (Figure
3e). These results indicate that PTN produced by fibroblasts
may exert its biological effect on peritoneal mesothelial cells
in the process of peritoneal fibrosis.
Finally, we examined whether PTN has a crucial role in
peritoneal fibrosis progression. PTN knockout mice were
treated with CG three times a week for 4 weeks. Although the
thickness of peritoneal membrane in PTN knockout mice was
similar compared with wild-type mice (Figure 4a and b), the
expression of tumor necrosis factor-a and IL-1b mRNA was
significantly reduced in CG-injected PTN knockout mice at 4
weeks, suggesting that PTN was involved in the inflammatory
process (Figure 4c). Furthermore, gene expression of
profibrotic factors, TGF-b1, connective tissue growth factor
in CG-injected PTN knockout mice was reduced compared
with CG-injected wild-type mice (Figure 4c). Fibronectin and
type I collagen a1 chain were also decreased in CG-treated
RT M (–) (+)
Standard (ng)
1
PTN
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Figure 2 |PTN expression in human peritoneum and in peritoneal dialysate effluent. (a) Pleiotrophin (PTN) mRNA expression is
detected by reverse transcriptase-polymerase chain reaction in human peritoneal biopsy sample. M, DNA marker (100 bp DNA ladder), RT
() reverse transcriptase (), RT (þ ) reverse transcriptase (þ ). (b) Immunohistochemical study for PTN in the peritoneal biopsy sample
from a 5-year peritoneal dialysis (PD) patient A. (c) Western blot analysis for PTN in peritoneal dialysate effluent. Patient B was a 54-year-old
woman suffering from nephrosclerosis with a 2-year PD duration, patient C was a 47-year-old man suffering from diabetic nephropathy with
a 2-year PD duration, and patient D was a 29-year-old woman suffering from immunoglobulin A nephropathy with a 1-year PD duration.
Patients E and F suffered from peritonitis by Staphylococcus aureus, and their PD efferents were shown on the first day of the peritonitis.
Patient E was an 80-year-old woman suffering from nephrosclerosis with a 3-year PD duration. Patient F was an 86-year-old woman
suffering from diabetic nephropathy with a 4-year PD duration.
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PTN knockout mice. On the other hand, expression of type
IV collagen a1 chain was increased with the CG injection and
was similar between wild-type and PTN knockout mice with
CG treatment (Figure 4c). Macrophage infiltration was
assessed by immunohistochemical study for F4/80. The
number of macrophages in the peritoneum was increased
in CG-injected wild-type mice. The number tended to
decrease, but not significantly altered in CG-injected PTN
knockout mice at 4 weeks (Figure 5a–d and q). In contrast,
the number of CD3-positive T cells per the number of total
cells in submesothelial area in CG-treated PTN knockout
mice was significantly reduced compared with that in CG-
treated wild-type mice at 4 weeks (5.6±0.9 vs. 10.3±0.5;
Figure 5e–h and r). The effect of PTN on cell proliferation
was evaluated by immunohistochemical study for Ki-67, a
marker for cell proliferation (Figure 5i–l and s). Interestingly,
immunohistochemical study showed that Ki-67-positive cells
were localized within submesothelial compact zone and that
cells positive for Ki-67 were presumed to be fibroblast-like
cells according to their morphological appearance in
CG-treated wild-type mice. The number of Ki-67-positive
cells in CG-treated PTN-deficient mice was significantly
decreased compared with that in CG-treated wild-type mice
(1.5±1.1 vs. 3.8±1.2). Collagen IV deposition was similar
between CG-treated wild-type mice and CG-treated PTN-
deficient mice (Figure 5m–p). Peritoneal equilibration test
was conducted to examine the functional role of PTN on
peritoneal fibrosis at 2 weeks after the first CG injection.
Figure 6 showed that the ratio of creatinine concentrations
in the dialysate multiplied by dialysate volume over the
plasma creatinine (D Cr  volume/P Cr) in PBS-treated
PTN-deficient mice was not different from that in PBS-
treated wild-type mice. In contrast, D Cr  volume/P Cr
in CG-treated PTN-deficient mice was lower than that in
CG-treated wild-type mice (1.93±0.15 vs. 2.33±0.38),
suggesting that PTN deficiency was associated with low
peritoneal transport in peritoneal fibrosis.
These results suggest that PTN has a crucial role in cell
proliferation, extracellular matrix production, and peritoneal
permeability during the development of peritoneal fibrosis
through inflammatory process.
DISCUSSION
In this study, we identify for the first time that PTN is
expressed in peritoneal tissues in mice and humans, especially
in experimental peritoneal fibrosis mouse model. Mice
receiving intraperitoneal infusion of PDF also showed
increased expression of PTN, suggesting that PTN could be
involved in peritoneal injury induced by dialysis solution.
PTN is an 18- or 15-kDa heparin-binding protein.11,14 PTN
is initially identified as a neurite growth/guidance-regulating
protein and belongs to the midkine family.15,16 PTN has
diverse functions including proliferation, mitogenic activ-
ities, apoptosis, oncogenic activity, and angiogenic activity.11
PTN has been shown to have an important role in
embryogenesis and kidney development.17 PTN-deficient
mice have been shown to have lower threshold for induction
of long-term potentiation in hippocampal slices.18 Other
reports show that PTN-deficient mice exhibit less migration
of neutrophils and macrophages to liver after partial
hepatectomy,19 and that female mice deficient in both
midkine and PTN are infertile.13
The long-term PD can cause deterioration of the
peritoneum,20 and is closely associated with high peritoneal
transport rate, which is one of the risk factors for developing
encapsulating peritoneal sclerosis.21 To evaluate the degree of
peritoneal damage, several biomarkers have been investi-
gated. Dialysate concentrations of IL-6 and vascular endo-
thelial growth factor have been shown to be associated with
increased peritoneal transport rate.4 Dialysate fibrinogen/
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Figure 3 |PTN, Ptprz1, and syndecan-3 expression in cultured
cells. The effect of pleiotrophin (PTN) on cell proliferation and
migration in cultured mesothelial cells. (a) Ptprz1 mRNA
expression was quantified by real-time reverse transcriptase-
polymerase chain reaction (RT-PCR) in cultured mesothelial cells,
NIH3T3 fibroblasts, RAW264.7, BW5147, BCL1-20, and bEnd.3 cells
(n¼ 6, each). (b) Syndecan-3 (Sdc3) mRNA expression was
quantified by real-time RT-PCR in cultured mesothelial cells,
NIH3T3 fibroblasts, RAW264.7, BW5147, BCL1-20, and bEnd.3 cells
(n¼ 6, each). (c) The effect of PTN on cell proliferation in
cultured mesothelial cells. Mesothelial cells were treated with PTN
(1 ng/ml), platelet-derived growth factor (PDGF)-BB (50 ng/ml),
angiotensin II (Ang II, 106mol/l), endothelial growth factor
(EGF, 100 ng/ml), or vehicle (Veh.). 3H-thymidine incorporation
was assessed (n¼ 6, each). (d) The effect of PTN on cell migration
in cultured mesothelial cells by modified Boyden chamber
method. Mesothelial cells were treated with PTN (1 ng/ml),
PDGF-BB (50 ng/ml), angiotensin II (106mol/l), or EGF (100 ng/ml)
(n¼ 6, each). (e) PTN mRNA expression was quantified by
real-time RT-PCR in cultured mesothelial cells, NIH3T3 fibroblasts,
RAW264.7, BW5147, BCL1-20, and bEnd.3 cells (n¼ 6, each).
Mean±s.e. *Po0.05, **Po0.01 vs. vehicle. #Po0.05, ##Po0.01 vs.
NIH3T3 fibroblasts, BW264.7, BW5147, BCL1-20 or bEnd.3.
wwPo0.01 vs. mesothelial cells, RAW264.7, BW5147, BCL1-20 or
bEnd.3. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
164 Kidney International (2012) 81, 160–169
or ig ina l a r t i c l e H Yokoi et al.: PTN in peritoneal fibrosis
fibrin degradation products also correlate with increased
peritoneal permeability.22 IL-6 is an acute-phase inflamma-
tory reaction protein. The dialysate and ascite levels of
inflammatory and fibrinolysis markers have been reported to
increase before the development of encapsulating peritoneal
sclerosis.23 Although levels of inflammatory, angiogenic, and
fibrinolytic markers such as IL-6, vascular endothelial growth
factor, and fibrin degradation products could be important
biomarkers for developing encapsulating peritoneal sclerosis,
key molecules involved in the process of peritoneal damage
are still elusive. In this study, we performed microarray
analysis to identify genes differentially expressed between
PBS-treated and CG-treated mice and expressed in cultured
mesothelial cells. Procollagen type VIII a1 gene and IL-6 were
upregulated by 73.5- and 25.9-fold, respectively. These genes
have been already reported under peritoneal damage,
indicating that our microarray analysis is consistent with
previous reports.4,24 Genes identified by microarray analysis
can be candidate ones for elucidating the development and
progression of peritoneal fibrosis. In this study, we detected
increased PTN mRNA expression and protein levels by 42-
and 4-fold, respectively. The discrepancy between mRNA and
protein levels may come from long half-life of the protein.25
Our study revealed that human peritoneal biopsy samples
contained PTN mRNA and protein. PTN protein in human
peritoneum was located at mesothelial cells and fibroblasts,
consistent with mouse peritoneal fibrosis model. We also
revealed that PTN was detected in overnight-dwell peritoneal
dialysate and that the main form of PTN in peritoneal
dialysate is 15 kDa. Previously, Lu et al.14 have demonstrated
that PTN15 promotes glioblastoma proliferation in an ALK-
dependent manner, whereas PTN18 promotes migration
in a Ptprz1-dependent manner. Peritoneal dialysates from
patients with peritonitis may contain high levels of PTN.
PTN mRNA expression was increased in peritoneal
fibrosis model mice mainly at fibroblasts. In vitro study also
showed that PTN expression was abundant in cultured
fibroblasts compared with cultured mesothelial cells, lymp-
hocytes, and macrophages. PTN gene expression has been
shown to be upregulated in NIH3T3 fibroblasts stimulated by
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Figure 4 |Histological appearance and mRNA expression of peritoneum in PTN knockout mice (C57BL/6J background).13
Pleiotrophin (PTN) knockout mice were treated with chlorhexidine gluconate (CG) three times a week for 4 weeks. (a) Masson’s trichrome
staining of peritoneum in wild-type or PTN knockout mice treated with phosphate-buffered saline (PBS) or CG. (b) The thickness of
peritoneal membrane in mice. (c) Real-time reverse transcriptase-polymerase chain reaction analyses of interleukin (IL)-1b, tumor necrosis
factor (TNF)-a, transforming growth factor (TGF)-b1, connective tissue growth factor (CTGF), fibronectin, a1(I) collagen (COL1A1), and a1(IV)
collagen (COL4A1). GAPDH was used as control. WT PBS: n¼ 5, KO PBS: n¼ 4, WT CG: n¼ 11, KO CG: n¼ 10. Mean±s.e. **Po0.01 vs.
PBS-treated mice with the same genotype. #Po0.05, ##Po0.01. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; KO, PTN knockout
mice; WT, wild-type mice.
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platelet-derived growth factor-AB.26 A recent paper reveals
that PTN expression is strongly associated with IFN-g/JAK/
STAT1 signaling.27 Further investigations are necessary to
elucidate the molecular mechanism of PTN induction. PTN
is a ligand of the RPTPb/z,12,28 ALK12, and syncecan-3.12 Our
study showed that RPTPb/z was expressed in mesothelial
cells, not in cultured fibroblasts, lymphocytes, or macro-
phages, and that syndecan-3 highly existed in mesothelial
cells and was weakly expressed in fibroblasts and macro-
phages. ALK29 was not detected in these cells. Taken together,
PTN secreted by fibroblasts in submesothelial layer can
have an effect on proliferation and migration mainly in
mesothelial cells that express RPTPb/z and syndecan-3.30
The role of PTN receptors in peritoneal fibrosis needs further
clarification.
In this study, the role of PTN in peritoneal fibrosis was
investigated by using PTN-deficient mice. Without PTN,
inflammatory and profibrotic responses were significantly
reduced at 4 weeks after CG treatment, suggesting that PTN
aggravates inflammation and fibrosis in the development of
peritoneal fibrosis. Increased peritoneal permeability, exam-
ined by peritoneal equilibration tests, in CG-treated wild-
type mice was almost completely ameliorated in CG-treated
PTN knockout mice, suggesting that PTN can increase
peritoneal permeability. Although CG-injected PTN knock-
out mice showed lower expression of COL1A1 and
fibronectin than wild-type mice, the thickness of peritoneal
membranes did not change between PTN-deficient mice and
wild-type mice. The reason may come from similar
expression levels of some other types of extracellular matrix
such as collagen IV. Type IV collagen is abundantly deposited
in peritoneal membrane.31,32 Although macrophage infiltra-
tion has been shown to be an important phenomenon in
peritoneal fibrosis,33 CG-treated PTN-deficient mice showed
no apparent difference in macrophage infiltration compared
with wild-type mice. T cells are also an important part of
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Figure 5 | Immunohistochemical study of F4/80, CD3, Ki-67, and type IV collagen (Col4). Mice were treated with chlorhexidine
gluconate (CG) three times a week for 4 weeks. (a–d) F4/80, (e–h) CD3, (i–l) Ki67, and (m–p) Col4 staining in the peritoneum from (a, e, i, and
m) phosphate-buffered saline (PBS)-injected wild-type (WT) mice, (b, f, j, and n) PBS-injected PTN knockout (KO) mice, (c, g, k, and o)
CG-injected WT mice, (d, h, l, and p) CG-injected pleiotrophin (PTN)-KO mice. Arrows indicate positive cells. (q) The number of F4/80-
positive cells per the number of total cells in the submesothelial area in mice. (r) The number of CD3-positive cells per the number of
total cells in the submesothelial area in mice. (s) The number of Ki67-positive proliferated cells in the submesothelial area in mice. WT PBS:
n¼ 5, KO PBS: n¼ 4, WT CG: n¼ 11, KO CG: n¼ 10. Mean±s.e. **Po0.01 vs. PBS-treated mice with the same genotype in Figure 5. #Po0.05.
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peritoneal membrane damage,34,35 and our results showed
that T-cell infiltration was reduced in CG-treated PTN-
deficient mice. PTN has been shown to induce expression of
inflammatory cytokines in peripheral blood mononuclear
cells.36 The mechanism of T-cell infiltration by PTN is not
clear, because RPTPb/z mRNA nor syndecan-3 are not
detected in cultured T-cell line. Downstream mediators of
PTN need to be investigated in the future study. Cell
proliferation was assessed by Ki-67 immunostaining.37 PTN-
deficient mice showed lower expression of Ki-67, indicating
that cell proliferation in submesothelial layer was inhibited
without PTN.
In conclusion, this study shows that PTN expression is
upregulated in a mouse model of peritoneal fibrosis and is
present in human peritoneal tissues and in peritoneal
dialysate effluent, and that PTN secreted by fibroblasts or
mesothelial cells can have a proliferative and chemotactic
effect on mesothelial cells, and that PTN-deficient mice
exhibit a weaker peritoneal membrane damage. These
findings can be a help to elucidate a novel pathway in
peritoneal fibrosis and suggest that PTN could be a
promising biomarker against peritoneal damage.
MATERIALS AND METHODS
Patients
Patients who were admitted to Kyoto University Hospital for the
diagnosis and treatment of renal disorders were enrolled under
informed consent. This study was approved by the ethics committee
on human research of Kyoto University Graduate School of
Medicine. The parietal peritoneal samples were taken from the
insertion site of a PD catheter located in the lumbar region as
biopsies at the beginning or ending of PD. Peritoneal dialysate
effluents were obtained at the time of the exchange. Expression of
PTN in peritoneal biopsy sample was assessed by the RT-PCR
method. After RNA extraction by RNeasy mini kit (Qiagen,
Valencia, CA), complementary DNA was generated using the
SuperScript II Reverse Transcriptase (Invitrogen, Carlsbad, CA)
according to the manufacturer’s instruction. RT-PCR was performed
using the following primers: forward, 50-gggaagaaagagaccagtgagt-30
and reverse, 50-ctggtttctctttcttccctgc-30.
Induction of peritoneal fibrosis and phenotypic analysis
All animal experiments were approved by the animal experimenta-
tion committee of Kyoto University Graduate School of Medicine.
Peritoneal fibrosis was induced in mice with the intraperitoneal
injections of 0.3ml of 0.1% CG in 15% ethanol and 85% PBS three
times a week for 1, 2, 3, and 4 weeks as previously reported (n¼ 5,
each).38 For evaluating dose–response, mice were administered
0.3ml of 0.01% and 0.03% CG in 15% ethanol and 85% PBS three
times a week for 4 weeks. Control mice received intraperitoneal
injection of PBS. Mice were killed under pentobarbital anesthesia,
and peritoneal tissues were obtained from the upper portion of the
parietal peritoneum to avoid injured peritoneum by repeated
injections.
For dialysis fluid infusion, silicone port catheters with two cuffs
were used (PennyPort MMP-4S; Access Technologies, Skokie, IL).
After mice were anesthetized under pentobarbital, an incision was
made in the skin of the back and left lumbar portion. Peritoneal
membrane was pricked with a 20-Gy needle to make a small hole.
The catheter port was implanted under the skin of the back and the
catheters were inserted along the needle hole. A catheter port was
placed subcutaneously on the back. One milliliter of PDFs (Perisate;
JMS, Hiroshima, Japan) containing 7% PD solution or PBS were
administered intraperitoneally via a catheter port using a 26-Gy
needle every day for 4 weeks (n¼ 5, each). PTN-deficient mice
(C57BL/6J background) were generated as described previously.13
Modified peritoneal equilibration test
Modified peritoneal equilibration test was conducted to determine
the peritoneal permeability. Wild-type or PTN knockout mice were
injected with PBS or CG (n¼ 5, each) three times for 2 weeks, and
were then administered intraperitoneal injection of 3ml of 7%
glucose dialysis solution (Perisate; JMS). After 2 h of retention,
dialysis fluids were collected and blood samples were withdrawn.
Serum and dialysate creatinine levels were measured by using the
enzymatic method (SRL, Tokyo, Japan).
Affymetrix gene chip array
Wild-type mice were subjected to peritoneal fibrosis with the
intraperitoneal injections of 0.3ml of 0.1% CG in 15% ethanol and
85% PBS three times a week for 3 weeks (n¼ 3). As control, PBS-
treated wild-type mice were used (n¼ 3). Total RNA from the
parietal peritoneum at day 21 was extracted by RNeasy Mini Kit
(Qiagen) in these mice.39 Complementary RNA probes were
generated using the GeneChip Expression 30-Amplification Reagents
for IVT Labeling Kit (Applied Biosystems, Foster city, CA) and each
sample was hybridized to an Affymetrix mouse genome 430 2.0
array at TAKARA Bio (Shiga, Japan). After washing, the genechips
were scanned by a GeneChip Scanner 3000. Data normalization, log
transformation, statistical analysis, and pattern study were per-
formed with the GeneChip Operating Software.
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Figure 6 |Modified peritoneal equilibration test (PET). D Cr 
volume/P Cr represents the creatinine (Cr) level of 7% glucose
dialysate effluent (D) multiplied by volume divided by that of
plasma (P) level in mice at 2 h retention. Chlorhexidine gluconate
(CG)-injected wild-type (WT) mice showed increased D Cr 
volume/P Cr compared with phosphate-buffered saline (PBS)-
injected mice. Pleiotrophin (PTN)-knockout (KO) mice treated with
CG showed reduced D Cr  volume/P Cr level compared with WT
mice with CG. WT PBS: n¼ 3, KO PBS: n¼ 6, WT CG: n¼ 5, KO CG:
n¼ 7. Mean±s.e. *Po0.05 vs. PBS-treated mice with the same
genotype in Figure 6. #Po0.05.
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Histology and immunohistochemistry
Peritoneal membrane sections were fixed with 4% buffered
paraformaldehyde and embedded in paraffin. Sections (1mm thick)
were stained with Masson’s trichrome.40 We measured the thickness
of the fibrotic submesothelial zone above the abdominal muscle
layer in cross-sections as described previously,41 by using Meta-
Morph software (Molecular Devices, Downingtown, PA). Ten
different points were examined by two investigators without
knowledge of the origin of the slides. The results were expressed
as the average peritoneal membrane thickness. For immunohisto-
chemical analyses of PTN, collagen type IV, F4/80, CD3, and Ki-67
in mice, the sections were processed as described.40 After antigen
retrieval, the samples were incubated with rabbit polyclonal anti-
PTN antibody (ProteinTech Group, Chicago, IL), rabbit polyclonal
anti-mouse collagen type IV antibody (Millipore, Billerica, MA), rat
monoclonal anti-F4/80 antibody (Serotec, Oxford, UK), rabbit
polyclonal anti-CD3 antibody (DAKO, Glostrup, Denmark), and rat
monoclonal anti-Ki-67 antibody (DAKO). After incubation with
horseradish peroxidase-conjugated secondary antibodies, the speci-
mens were developed using 3,30-diaminobenzidine tetrahydrochlo-
ride. For immunohistochemical study of human PTN, we used a
rabbit polyclonal anti-PTN antibody (Abcam, Cambridge, UK) as a
primary antibody.
Real-time PCR analysis
Quantitative real-time PCR was performed using Premix Ex Taq
(TAKARA Bio) on an Applied Biosystems 7300 real-time PCR
system (Applied Biosystems) or a StepOnePlus system (Applied
Biosystems), as described previously with some modification.39
To determine mouse PTN, Ptprz1, TGF-b1, connective tissue
growth factor, COL1A1, COL4A1, fibronectin, and IL-1b and
tumor necrosis factor-a expression levels, gene-specific primers
and probes were used. Primers and probe sequences are listed in
Supplementary Table S1 online. Expression of each mRNA was
normalized for glyceraldehyde-3-phosphate dehydrogenase using
TaqMan Rodent glyceraldehyde-3-phosphate dehydrogenase control
reagents (Applied Biosystems).
Western blot analysis
Western blot analysis was performed as described.39 Filters trans-
ferred onto protein extracts or peritoneal dialysate effluents were
incubated with rabbit polyclonal anti-PTN antibody (ProteinTech
Group) and mouse monoclonal anti-glyceraldehyde-3-phosphate
dehydrogenase antibody (Santa Cruz Biotechnology, Santa Cruz,
CA). Immunoblots were then developed using a chemiluminescence
kit (GE healthcare, Piscataway, NJ).
Cell culture
Mouse peritoneal mesothelial cells were obtained using a standard
trypsin/ethylenediaminetetraacetic acid digestion method from the
peritoneal wall of adult male C57BL/6J mice.42,43 The excised
peritoneal flap was cut into small pieces and then incubated, with
constant agitation, with 0.25% trypsin and 1mmol/l ethylenedia-
minetetraacetic acid (Invitrogen) for 15min at 37 1C. The released
cells were centrifuged at 1200 r.p.m. for 5min and cultured with
Dulbecco’s Modified Eagle Medium (DMEM D6046; Sigma-Aldrich,
St Louis, MI) supplemented with 10% fetal bovine serum (FBS),
penicillin (100U/ml), streptomycin (100 mg/ml), and amphotericin
B (25 ng/ml). NIH3T3 fibroblasts, RAW264.7 cells, and bEnd.3 cells
were obtained from American Type Culture Collection (Manassas,
VA). BW5147 cells were provided by Health Science Research Bank
(Sennan, Osaka, Japan) and BCL1-B20 cells were provided by the
RIKEN BRC through the National Bio-Resource Project of the
Ministry of Education, Culture, Sports, Science and Technology,
Japan. BCL1-B20 cells were cultured with RPMI1640 (Sigma) with
10% FBS. Other cells were cultured with DMEM with 10% FBS.
Proliferation assay in cultured mesothelial cells was performed
with 3H-thymidine as described previously.44 Briefly, mesothelial
cells were plated on 24-well plates (n¼ 6, each group) and incubated
with DMEM containing 0.3% FBS for the 24 h. Cell proliferation was
studied in the presence of 1 ng/ml of recombinant human PTN
(R&D Systems, Minneapolis, MN), 10ng/ml of recombinant human
platelet-derived growth factor-BB (BD Biosciences, San Jose, CA),
106mol/l of angiotensin II (Peptide Institute, Osaka, Japan), 100ng/ml
of recombinant human endothelial growth factor (PeproTech EC,
London, UK), or vehicle (PBS) for 24 h with DMEM containing
0.3% FBS. 3H-thymidine was added simultaneously with the
above-described agents. Migration assay was performed as described
previously.45 In brief, migration of mesothelial cells was analyzed
by modified Boyden chamber method using 96-well chemotaxis
chambers. In the upper chambers, mesothelial cells were placed
with DMEM containing 0.02% bovine serum albumin. In the
lower chambers, there were serum-free DMEM containing PTN
(1 ng/ml), platelet-derived growth factor-BB (50 ng/ml), angiotensin
II (106mol/l), or endothelial growth factor (100 ng/ml). The cells
were incubated for 4 h and the filters were stained with 0.5%
Coomassie Brilliant Blue R250 (Nacalai Tesque, Kyoto, Japan) in
50% methanol, 40% water, and 10% acetic acid (n¼ 6, each).
Statistical analysis
Data are expressed as the mean±s.e. Statistical analysis was
performed using one-way analysis of variance as appropriate. A
P-value o0.05 was considered statistically significant.
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